City page
Solna biotech and pharma directory
This page shows why the city matters, which categories are strongest there, and which compliance or quality markers are already visible in public evidence.
Where does this city read strongest?
Therapeutics (2) and Diagnostics (1). Most visible records: Biosergen, Affibody, and Elypta.
Which standards and public evidence are already visible?
ISO-13485 (1). Latest review: 22 March 2026. Review cycle: March 2026.
Why does this city matter?
This page brings visible companies and infrastructure records into one practical view of Solna.
By category
Solna by category
Jump into a category page filtered to this country only.
Full list
Solna biotech and pharma directory
3 city records currently match the active filter.
Current review cycle
Biosergen
SolnaSwedenTherapeutics
Solna biotech company developing innovative antifungal therapeutics for life-threatening invasive fungal infections from a Swedish listed-company base.
- Lead
- Tine Kold OlesenChief Executive Officer
- Scale
- Clinical-stage therapeutics platform
Current review cycle
Affibody
SolnaSwedenTherapeutics
Solna protein-engineering company developing Affibody molecules for targeted therapeutics and molecular imaging from its Swedish operating base.
- Lead
- David BejkerPresident and CEO
- Scale
- Development-stage therapeutics platform
Current review cycle
Elypta
SolnaSwedenDiagnostics
Solna molecular-diagnostics company developing metabolism-based liquid biopsy tests for earlier cancer detection and recurrence monitoring from the Karolinska campus.
- Lead
- Karl BergmanCEO
- Scale
- Diagnostics development platform
Related briefs
Briefs that mention Solna
Nordic Biotech Landscape 2026: Denmark, Sweden, Finland, Norway
A practical map of the Nordic biotech and pharma landscape in 2026 — 124 operators across Denmark, Sweden, Finland, and Norway, anchored by Novo Nordisk, Genmab, Lundbeck, AstraZeneca Gothenburg, Bavarian Nordic, Orion, and a dense Medicon Valley + Karolinska cluster layer.
Open briefEuropean Anti-Infectives & AMR 2026: Antibacterials, Antifungals, Sepsis, and Pathogen Diagnostics
A practical map of the European anti-infectives and antimicrobial resistance sector in 2026 — Basilea (Cresemba, Zevtera), BioVersys, Biosergen, Modus Therapeutics, AlgiPharma, plus the rapid molecular diagnostics + AMR detection layer.
Open briefNext step
Read the city, then widen the view.
Use country and regional pages for wider context, and the company suggestion form for new candidate records.